Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.56 |
| ▸ | JAK2 | O60674 | 6/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.56 |
| ▸ | JUN | P05412 | 4/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.56 |
| ▸ | AXL | P30530 | 2/20 | 0.54 |
| ▸ | TTK | P33981 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 2/20 | 0.51 |
| ▸ | JAK3 | P52333 | 2/20 | 0.51 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.51 |
| ▸ | BRD2 | P25440 | 1/20 | 0.51 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633250 | 0.91 | AXL (0.52) | BRD4JAK2MAPK10JUNMAPK8 | |
| SCHEMBL29370855 | 0.88 | TTK (0.61) | BRD4JAK2MAPK10JUNMAPK8 | |
| SCHEMBL18376727 | 0.88 | TTK (0.61) | BRD4JAK2MAPK10JUNMAPK8 | |
| SCHEMBL18376233 | 0.82 | JAK2 (0.63) | BRD4JAK2MAPK10JUNMAPK8 | |
| SCHEMBL1633468 | 0.82 | MAPK10 (0.51) | BRD4JAK2MAPK10JUNMAPK8 | |
| SCHEMBL18377031 | 0.80 | JAK2 (0.55) | BRD4JAK2MAPK10JUNMAPK8 | |
| SCHEMBL29847439 | 0.80 | MAPK10 (0.79) | BRD4JAK2MAPK10JUNMAPK8 | |
| SCHEMBL16513631 | 0.80 | MAPK10 (0.79) | BRD4JAK2MAPK10JUNMAPK8 | |
| SCHEMBL1633913 | 0.80 | JAK3 (0.48) | JAK2MAPK10JUNMAPK8FGFR1 | |
| SCHEMBL18376659 | 0.79 | BRD4 (0.49) | BRD4JAK2MAPK10JUNMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | BRD4 268/4885JAK2 1352/4885MAPK10 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.